Recent pages

Company Name

D/DeCODE Genetics (DCGN)

Edit
page

New
page

Print
page

This page was last modified over a year ago by Sysop

DeCODE Genetics (DCGN)

This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below.

From 1

1. Company Information:
2. Company Overview:

2.1. Company Products/Services/Markets:
2.2. Strategy:
2.3. Competitors:
2.4. Industry Trends and News:
2.5. Acquisitions, Divestitures, Major Transactions, Spin-offs :
2.6. Management – Pros & Cons, Changes:

5.1. Buy Rationale:
5.2. Sell Rationale:

6. Projected Financials:
7. Discussion:
8. Footnotes:
9. News:
10. See Also (links to blogs, forums, external sources, etc...):

Company Information:

Company Address:

Sturlugata 8

Reykjavik, IS-101

Company’s Web Address: http://www.decode.com/

Industry Sector:

Fiscal Year:

Dividend:

Note: this section is not editable. Please click here to report any inaccuracies.

Shares Outstanding: 61,700,000
Market Capitalization: Updating...

Income Statements
Click for: Annual Income Statement
Click for: Quarterly Income Statement

Balance Sheets
Click for: Annual Balance Sheet
Click for: Quarterly Balance Sheet

Cash Flow Statements
Click for: Annual Cash Flow Statement
Click for: Quarterly Cash Flow Statement

SEC Filings
Click for: Form 10-Ks
Click for: Form 10-Qs
Click for: Annual Proxy Statements
Link to SEC filings search: http://www.sec.gov/cgi-bin/srch-edgar

Company Overview:

Note: this section is not editable.

Formed in 1996, biotechnology company deCODE genetics, Inc. (DCGN) focuses on identifying the genetic causes of common diseases such as asthma, hypertension, and stroke, and accordingly engages in developing drugs for the treatment of these diseases. The company is using population genetics (genetic changes that happen to a population over time) to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services in pharmaceuticals, gene and drug discovery, DNA-based diagnostics, pharmacogenomic, bioinformatics, and clinical trials. The company has both Drug Discovery and Contract Research operations. Encode, the company's contract research organization (CRO) incorporates pharmacogenomic data to design "information rich" clinical trials. The company uses biomarkers to identify patients for optimal efficacy and drug response. Encode also develops potential pharmacogenomic (DNA) tests to be used in tandem with the drug. Encode customers include Merck, Wyeth, Pfizer, and Vertex Pharmaceuticals. The drug discovery division has both clinical and preclinical stage candidates, as well as an alliance with Roche Diagnostics. Based in Reykjavik, Iceland, the company employed 431 people as of December 31, 2007. However, the company announced a reduction in staff of 60 people on February 29, 2008.

Read full report on deCODE genetics

Company overview provided by

Company Products/Services/Markets:

Enter Company Products/Services Here

Strategy:

Describe Key Aspects of Company's Strategy Here

Competitors:

Enter Competitors Here

Industry Trends and News:

Enter Industry Trends and News Here

Acquisitions, Divestitures, Major Transactions, Spin-offs :

Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here

Management – Pros & Cons, Changes:

Enter Management - Pros & Cons, Changes Here

Financial Analysis:

Enter Financial Analysis Here

Valuation:

Enter Valuation Analysis and Valuation Ratios Here

	2007	2006	2005
Price/Earnings
Price/EBITDA
Price/Pre-tax Income
Price/Revenue

Investment Rationale:

Buy Rationale:

Enter Buy Rationale Here

Sell Rationale:

Enter Sell Rationale Here

Projected Financials:

Income Statement: (Paste Here)

Balance Sheet: (Paste Here)

Cash Flow Statement: (Paste Here)

Financial Ratios: (Paste Here)

Other: (Paste Here)

Discussion:

This area is for debates regarding different recommendations for this stock.

Footnotes:

News:

Yahoo! Finance Blog
Add this Facebook Y! application to your profile In a tough market, I get by with a little help from my friends… The turbulence and wild swings of the world’s financial markets have been enough to make even the sturdiest of investors a little queasy as of late. If you haven’t already, you will likely lose most of your appetite for risk as [...]
Yahoo! Finance Goes Global At midnight on Tuesday, something great happened. Something BRILLIANT. Yahoo! Finance launched 15 new pages across Europe to some great user feedback. But it wasn’t just the pages that we should be rightly proud of –- it’s the united Global Yahoo! Finance team behind it; the upgraded processes and infrastructure behind the design. Engineers, [...]
Introducing Ticker Tape on the Quotes Pages We are excited to add a popular new feature to the top of all our quotes pages. Now you have faster and easier access to stocks you care most about. The new ticker tape, prominently placed, displays the most recent quotes you last looked at. This is the same useful functionality we offer [...]
Getting the most out of the Interactive Chart If you’ve clicked the thumbnail chart — or a time period link below it — on our quote page, you’ve likely visited our Interactive Chart. The Interactive Chart is a relatively new addition to Yahoo! Finance; it became generally available in April. There are several things you can do on the Interactive Chart that you [...]
Real-Time ECN Quotes Are Now Available on Multi-Quote and Portfolios Pages! Thanks to everyone for the great feedback on our recent real-time features on Yahoo! Finance. We know this is information you value, so today we’re pleased to build on our real-time features with the addition of Real-Time ECN views in multi-quote and portfolio pages on Yahoo! Finance. With the markets being volatile and earnings right around [...]